Institutional shares held 87.9 Million
2.34M calls
1.94M puts
Total value of holdings $3.29B
$87.5M calls
$72.3M puts
Market Cap $5.43B
145,274,000 Shares Out.
Institutional ownership 60.52%
# of Institutions 412


Latest Institutional Activity in TGTX

Top Purchases

Q2 2025
Imc Chicago, LLC Shares Held: 27.9K ($1.04M)
Q2 2025
State Of Alaska, Department Of Revenue Shares Held: 80.8K ($3.02M)
Q2 2025
Abound Wealth Management Shares Held: 3.51K ($131K)
Q2 2025
Klp Kapitalforvaltning As Shares Held: 30.8K ($1.15M)
Q2 2025
Nbc Securities, Inc. Shares Held: 3.02K ($113K)

Top Sells

Q2 2025
North Crest Asset Manangement, LLC Shares Held: 8.39K ($314K)
Q2 2025
Avaii Wealth Management, LLC Shares Held: 26.4K ($986K)
Q2 2025
Banque Pictet & Cie Sa Shares Held: 12.3K ($461K)
Q2 2025
Wealth Effects LLC Shares Held: 11K ($411K)
Q2 2025
Farther Finance Advisors, LLC Shares Held: 230 ($8.6K)

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.


Insider Transactions at TGTX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
918K Shares
From 7 Insiders
Grant, award, or other acquisition 918K shares
Sell / Disposition
155K Shares
From 6 Insiders
Bona fide gift 73.5K shares
Open market or private sale 81.4K shares

Track Institutional and Insider Activities on TGTX

Follow TG THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TGTX shares.

Notify only if

Insider Trading

Get notified when an Tg Therapeutics, Inc. insider buys or sells TGTX shares.

Notify only if

News

Receive news related to TG THERAPEUTICS, INC.

Track Activities on TGTX